Literature DB >> 11202458

62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases.

M A Flower1, J Zweit, A D Hall, D Burke, M M Davies, M J Dworkin, H E Young, J Mundy, R J Ott, V R McCready, P Carnochan, T G Allen-Mersh.   

Abstract

The aim of this study was to establish a quantitative positron emission tomography (PET) method for investigating angiotensin II (AII)-induced changes in blood flow distribution in the liver. This was in order to evaluate the role of vascular manipulation applied to locoregional chemotherapy treatment in patients with colorectal liver metastases. The tracer selected was copper-62 (II) pyruvaldehyde bis-(N4-methyl)thiosemicarbazone (62Cu-PTSM), which exhibits high first-pass extraction and tissue retention following intra-arterial administration. The short half-life of the tracer and its availability from a 62Zn/62Cu generator enabled short-interval repeat PET scans on patients in a single imaging session. Distribution of tracer within the liver was imaged in a single view using a PET camera with rotating large-area detectors. By optimisation of the acquisition protocol, it was possible to acquire sufficient data to produce good-quality images and to quantify tracer uptake with an accuracy of <10%. Reproducibility of the imaging method was assessed in a single patient in whom three consecutive 62Cu-PTSM PET scans were obtained, and in whom no vascular manipulation was performed. Sets of scans (before, during and immediately after a 45-min AII infusion) were obtained in nine patients to assess blood flow changes associated with prolonged vascular manipulation. Significant individual responses, varying in both the magnitude and the duration of flow change, were observed in the majority of cases (7/11 lesions; 7/9 patients). These findings illustrate the potential of 62Cu-PTSM and PET for pharmacological studies. The wide range of individual patient responses to AII infusion suggests that PET blood flow assessment would be of value for selecting patients in whom this procedure may be effective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11202458     DOI: 10.1007/s002590000410

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  15 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 2.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 3.  A brief overview of metal complexes as nuclear imaging agents.

Authors:  Douglas S MacPherson; Kimberly Fung; Brendon E Cook; Lynn C Francesconi; Brian M Zeglis
Journal:  Dalton Trans       Date:  2019-10-07       Impact factor: 4.390

4.  Scheduling of anticancer drugs: timing may be everything.

Authors:  Astrid A M Van der Veldt; Adriaan A Lammertsma; Egbert F Smit
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

5.  A comparison of PET imaging characteristics of various copper radioisotopes.

Authors:  Heather Ann Williams; Simon Robinson; Peter Julyan; Jamal Zweit; David Hastings
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-29       Impact factor: 9.236

Review 6.  The development of copper radiopharmaceuticals for imaging and therapy.

Authors:  Monica Shokeen; Thaddeus J Wadas
Journal:  Med Chem       Date:  2011-09       Impact factor: 2.745

7.  The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.

Authors:  Martijn R Meijerink; Hester van Cruijsen; Klaas Hoekman; Matthijs Kater; Cors van Schaik; Jan Hein T M van Waesberghe; Giuseppe Giaccone; Radu A Manoliu
Journal:  Eur Radiol       Date:  2006-10-27       Impact factor: 5.315

8.  Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT.

Authors:  Wellington K Hsu; Mandeep S Virk; Brian T Feeley; David B Stout; Arion F Chatziioannou; Jay R Lieberman
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

9.  PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator.

Authors:  Terence Z Wong; Jeffrey L Lacy; Neil A Petry; Thomas C Hawk; Thomas A Sporn; Mark W Dewhirst; Gordana Vlahovic
Journal:  AJR Am J Roentgenol       Date:  2008-02       Impact factor: 3.959

10.  Rapid Multi-Tracer PET Tumor Imaging With F-FDG and Secondary Shorter-Lived Tracers.

Authors:  Noel F Black; Scott McJames; Dan J Kadrmas
Journal:  IEEE Trans Nucl Sci       Date:  2009-10-01       Impact factor: 1.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.